Literature DB >> 18303031

Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials.

S Collette1, F Bonnetain, X Paoletti, M Doffoel, O Bouché, J L Raoul, P Rougier, F Masskouri, L Bedenne, J C Barbare.   

Abstract

OBJECTIVE: The objective of this study was to assess the performance of three staging systems [Okuda, Cancer of the Liver Italian Program (CLIP) and Barcelona Clinic Liver Cancer group (BCLC)], for predicting survival in patients with hepatocellular carcinoma (HCC) and to explore how to improve prognostic classification among French patients with HCC whose main etiology is alcoholic cirrhosis.
METHODS: We have pooled two randomized clinical trials in palliative condition from the Fédération Francophone de Cancerologie Digestive. They had included 416 and 122 patients. Performances of Okuda, CLIP and BCLC scores have been compared using Akaike information criterion, discriminatory ability (Harrell's C and the Royston's D statistics), monotonicity of gradients and predictive accuracy (Schemper statistics Vs). To explore how to improve classifications, univariate and multivariate Cox model analyses were carried out.
RESULTS: The pooled database included 538 patients. The median survival was 5.3 months (95% confidence interval 4.6-6.2). For all statistics CLIP staging system had a better prognostic ability. Performances of all staging systems were rather disappointing. World Health Organization performance status (WHO PS) for CLIP or alpha-fetoprotein for BCLC allowed a significant improvement of prognostic information.
CONCLUSION: Our results indicate that CLIP staging seems to be most adapted to palliative setting and that it could be better by associating WHO PS.

Entities:  

Mesh:

Year:  2008        PMID: 18303031     DOI: 10.1093/annonc/mdn030

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  35 in total

1.  Advanced hepatocellular carcinoma: which staging systems best predict prognosis?

Authors:  Fidel-David Huitzil-Melendez; Marinela Capanu; Eileen M O'Reilly; Austin Duffy; Bolorsukh Gansukh; Leonard L Saltz; Ghassan K Abou-Alfa
Journal:  J Clin Oncol       Date:  2010-05-10       Impact factor: 44.544

2.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

Authors:  Al B Benson; Thomas A Abrams; Edgar Ben-Josef; P Mark Bloomston; Jean F Botha; Bryan M Clary; Anne Covey; Steven A Curley; Michael I D'Angelica; Rene Davila; William D Ensminger; John F Gibbs; Daniel Laheru; Mokenge P Malafa; Jorge Marrero; Steven G Meranze; Sean J Mulvihill; James O Park; James A Posey; Jasgit Sachdev; Riad Salem; Elin R Sigurdson; Constantinos Sofocleous; Jean-Nicolas Vauthey; Alan P Venook; Laura Williams Goff; Yun Yen; Andrew X Zhu
Journal:  J Natl Compr Canc Netw       Date:  2009-04       Impact factor: 11.908

Review 3.  Staging systems of hepatocellular carcinoma: a review of literature.

Authors:  Marcello Maida; Emanuele Orlando; Calogero Cammà; Giuseppe Cabibbo
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

4.  Reassessing hepatocellular carcinoma staging in a changing patient population.

Authors:  Ahmed O Kaseb; Neeraj N Shah; Hesham M Hassabo; Jeffrey S Morris; Lianchun Xiao; Yasmin M Abaza; Khalid Soliman; Ju-Seog Lee; Jean-Nicholas Vauthey; Michael Wallace; Thomas A Aloia; Steven Curley; James L Abbruzzese; Manal M Hassan
Journal:  Oncology       Date:  2014-01-08       Impact factor: 2.935

Review 5.  Staging systems for hepatocellular carcinoma: Current status and future perspectives.

Authors:  Akiyoshi Kinoshita; Hiroshi Onoda; Nao Fushiya; Kazuhiko Koike; Hirokazu Nishino; Hisao Tajiri
Journal:  World J Hepatol       Date:  2015-03-27

Review 6.  Treatment of intermediate-stage hepatocellular carcinoma.

Authors:  Alejandro Forner; Marine Gilabert; Jordi Bruix; Jean-Luc Raoul
Journal:  Nat Rev Clin Oncol       Date:  2014-08-05       Impact factor: 66.675

7.  Evaluation of seven different staging systems for alpha-fetoprotein expression in hepatocellular carcinoma after hepatectomy.

Authors:  Jianguo Zhou; Tao Yan; Xinyu Bi; Hong Zhao; Zhen Huang; Yefan Zhang; Yuan Li; Li Feng; Jing Wang; Jianqiang Cai
Journal:  Tumour Biol       Date:  2013-01-16

Review 8.  Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides.

Authors:  Jean-Luc Raoul; Eveline Boucher; Yan Rolland; Etienne Garin
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-01       Impact factor: 46.802

9.  Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.

Authors:  C-H Hsu; T-S Yang; C Hsu; H C Toh; R J Epstein; L-T Hsiao; P-J Chen; Z-Z Lin; T-Y Chao; A-L Cheng
Journal:  Br J Cancer       Date:  2010-02-16       Impact factor: 7.640

10.  Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters.

Authors:  Ke Hao; John M Luk; Nikki P Y Lee; Mao Mao; Chunsheng Zhang; Mark D Ferguson; John Lamb; Hongyue Dai; Irene O Ng; Pak C Sham; Ronnie T P Poon
Journal:  BMC Cancer       Date:  2009-11-03       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.